BioCryst Pharmaceuticals
BCRX
#5073
Rank
โ‚ฌ1.37 B
Marketcap
6,52ย โ‚ฌ
Share price
-3.07%
Change (1 day)
-9.49%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of September 2025 : โ‚ฌ0.55 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is โ‚ฌ0.55 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31โ‚ฌ0.77 B4.12%
2023-12-31โ‚ฌ0.74 B7.99%
2022-12-31โ‚ฌ0.69 B31.95%
2021-12-31โ‚ฌ0.52 B130.52%
2020-12-31โ‚ฌ0.22 B200.71%
2019-12-31โ‚ฌ75.56 M39.83%
2018-12-31โ‚ฌ54.04 M18.49%
2017-12-31โ‚ฌ45.6 M-10.71%
2016-12-31โ‚ฌ51.07 M85.05%
2015-12-31โ‚ฌ27.6 M11.9%
2014-12-31โ‚ฌ24.66 M13.55%
2013-12-31โ‚ฌ21.72 M-4.22%
2012-12-31โ‚ฌ22.67 M-1.82%
2011-12-31โ‚ฌ23.1 M
2000-12-31โ‚ฌ0.01 M
1997-12-31โ‚ฌ0.08 M-66.67%
1996-12-31โ‚ฌ0.25 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
โ‚ฌ0.59 B 6.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚ฌ1.07 B 93.70%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
โ‚ฌ1.28 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚ฌ0.21 B-61.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
โ‚ฌ21.42 B 3,764.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚ฌ2.25 M-99.59%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚ฌ20.49 B 3,597.11%๐Ÿ‡ฌ๐Ÿ‡ง UK
Emergent BioSolutions
EBS
โ‚ฌ0.56 B 2.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
โ‚ฌ8.55 M-98.46%๐Ÿ‡บ๐Ÿ‡ธ USA